Tonix outlines TRAIL Phase II start in Q1 2027 enrolling ~3,300 for TNX-4800 as TONMYA patents run to 2034

Tonix Pharmaceuticals (NASDAQ:TNXP) reported its third quarter 2026 financial results on November 9, showcasing strong sales for its fibromyalgia treatment TONMYA while navigating higher expenses and a wider-than-expected loss. The company's revenue increased to $17.2 million, with TONMYA driving approximately $15 million in sales, marking a 37% quarter-over-quarter growth from the previous quarter.

In addition to TONMYA, Zembrace SymTouch and TOSYMRA contributed $2.2 million to the total net revenue. Despite the growth in TONMYA sales, the company reported a loss of $2.89 per share, exceeding analysts' estimate of a $2.43 loss by 18.93%. The loss was primarily due to increased R&D expenses, which rose 177% year-over-year to $25.8 million, and higher SG&A expenses, which climbed 77% to $45.6 million.

Although Tonix now has coverage for 53% of U.S. covered lives, representing 166 million people, the company's cash runway extends only into early third quarter 2027, raising concerns about its near-term financing needs.